AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNGX
  4. [Form 4] Soligenix, Inc. Insider Trading Activity

[Form 4] Soligenix, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.

The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:

  • September 20, 2025
  • December 20, 2025
  • March 20, 2026
  • June 20, 2026

This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.

Dettagli della Comunicazione Modulo 4: Jerome B. Zeldis, Direttore di Soligenix (SNGX), ha comunicato l'acquisizione di opzioni su azioni il 20 giugno 2025. L'insider ha ricevuto 17.647 opzioni su azioni con un prezzo di esercizio di 1,70 $ per azione.

Le opzioni hanno una scadenza di 10 anni che termina il 20 giugno 2035 e matureranno in quattro tranche uguali nelle seguenti date:

  • 20 settembre 2025
  • 20 dicembre 2025
  • 20 marzo 2026
  • 20 giugno 2026

Questa concessione di compensi basata su azioni allinea gli interessi del direttore con quelli degli azionisti, favorendo un potenziale investimento azionario a lungo termine. La comunicazione 猫 stata effettuata entro i termini richiesti dalla SEC, dimostrando la conformit脿 agli obblighi di segnalazione della Sezione 16(a).

Detalles de la Presentaci贸n del Formulario 4: Jerome B. Zeldis, Director de Soligenix (SNGX), report贸 la adquisici贸n de opciones sobre acciones el 20 de junio de 2025. El insider recibi贸 17,647 opciones sobre acciones con un precio de ejercicio de $1.70 por acci贸n.

Las opciones tienen un plazo de 10 a帽os que expira el 20 de junio de 2035, y se consolidar谩n en cuatro cuotas iguales en las siguientes fechas:

  • 20 de septiembre de 2025
  • 20 de diciembre de 2025
  • 20 de marzo de 2026
  • 20 de junio de 2026

Esta concesi贸n de compensaci贸n basada en acciones alinea los intereses del director con los de los accionistas mediante el potencial de propiedad accionaria a largo plazo. La presentaci贸n se realiz贸 dentro del plazo requerido por la SEC, demostrando cumplimiento con las obligaciones de reporte de la Secci贸n 16(a).

靹滌嫕 4 鞝滌稖 靹鸽秬靷暛: Soligenix(SNGX)鞚� 鞚挫偓鞚� Jerome B. Zeldis電� 2025雲� 6鞗� 20鞚检棎 欤检嫕毵れ垬靹犿儩甓� 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 雮措秬鞛愲姅 欤茧嫻 1.70雼煬鞚� 頄夓偓 臧�瓴╈溂搿� 17,647 欤检嫕毵れ垬靹犿儩甓�鞚� 攵�鞐皼鞎橃姷雼堧嫟.

鞚� 鞓奠厴鞚� 10雲� 毵岅赴搿� 2035雲� 6鞗� 20鞚检棎 毵岆霅橂┌, 雼れ潓 雱� 彀鞐� 瓯胳硱 霃欖澕頃� 牍勳湪搿� 甓岆Μ臧� 攵�鞐惄雼堧嫟:

  • 2025雲� 9鞗� 20鞚�
  • 2025雲� 12鞗� 20鞚�
  • 2026雲� 3鞗� 20鞚�
  • 2026雲� 6鞗� 20鞚�

鞚� 欤检嫕 旮半皹 氤挫儊 攵�鞐姅 鞚挫偓鞚� 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偆氅� 鞛リ赴鞝侅澑 欤检嫕 靻岇湢 臧�電レ劚鞚� 鞝滉车頃╇媹雼�. 鞝滌稖鞚� SEC 鞖旉惮 旮瓣皠 雮挫棎 鞚措（鞏挫牳 靹轨厴 16(a) 氤搓碃 鞚橂毳� 欷�靾橅暔鞚� 氤挫棳欷嶋媹雼�.

D茅tails du d茅p么t du formulaire 4 : Jerome B. Zeldis, directeur de Soligenix (SNGX), a d茅clar茅 l'acquisition d'options d'achat d'actions le 20 juin 2025. L'initi茅 a re莽u 17 647 options d'achat d'actions avec un prix d'exercice de 1,70 $ par action.

Les options ont une dur茅e de 10 ans, expirant le 20 juin 2035, et seront acquises en quatre versements 茅gaux aux dates suivantes :

  • 20 septembre 2025
  • 20 d茅cembre 2025
  • 20 mars 2026
  • 20 juin 2026

Cette attribution de r茅mun茅ration en actions aligne les int茅r锚ts du directeur avec ceux des actionnaires via un potentiel de d茅tention d'actions 脿 long terme. Le d茅p么t a 茅t茅 effectu茅 dans les d茅lais requis par la SEC, d茅montrant la conformit茅 aux obligations de d茅claration de la Section 16(a).

Details zur Form 4 Einreichung: Jerome B. Zeldis, Direktor von Soligenix (SNGX), meldete am 20. Juni 2025 den Erwerb von Aktienoptionen. Dem Insider wurden 17.647 Aktienoptionen mit einem Aus眉bungspreis von 1,70 $ pro Aktie gew盲hrt.

Die Optionen haben eine Laufzeit von 10 Jahren und laufen am 20. Juni 2035 ab. Sie werden in vier gleichen Raten zu folgenden Terminen unverfallbar:

  • 20. September 2025
  • 20. Dezember 2025
  • 20. M盲rz 2026
  • 20. Juni 2026

Diese aktienbasierte Verg眉tung richtet die Interessen des Direktors mit denen der Aktion盲re durch langfristiges Aktienbesitzpotenzial aus. Die Meldung erfolgte fristgerecht gem盲脽 den Anforderungen der SEC und entspricht den Berichtspflichten gem盲脽 Abschnitt 16(a).

Positive
  • None.
Negative
  • None.

Dettagli della Comunicazione Modulo 4: Jerome B. Zeldis, Direttore di Soligenix (SNGX), ha comunicato l'acquisizione di opzioni su azioni il 20 giugno 2025. L'insider ha ricevuto 17.647 opzioni su azioni con un prezzo di esercizio di 1,70 $ per azione.

Le opzioni hanno una scadenza di 10 anni che termina il 20 giugno 2035 e matureranno in quattro tranche uguali nelle seguenti date:

  • 20 settembre 2025
  • 20 dicembre 2025
  • 20 marzo 2026
  • 20 giugno 2026

Questa concessione di compensi basata su azioni allinea gli interessi del direttore con quelli degli azionisti, favorendo un potenziale investimento azionario a lungo termine. La comunicazione 猫 stata effettuata entro i termini richiesti dalla SEC, dimostrando la conformit脿 agli obblighi di segnalazione della Sezione 16(a).

Detalles de la Presentaci贸n del Formulario 4: Jerome B. Zeldis, Director de Soligenix (SNGX), report贸 la adquisici贸n de opciones sobre acciones el 20 de junio de 2025. El insider recibi贸 17,647 opciones sobre acciones con un precio de ejercicio de $1.70 por acci贸n.

Las opciones tienen un plazo de 10 a帽os que expira el 20 de junio de 2035, y se consolidar谩n en cuatro cuotas iguales en las siguientes fechas:

  • 20 de septiembre de 2025
  • 20 de diciembre de 2025
  • 20 de marzo de 2026
  • 20 de junio de 2026

Esta concesi贸n de compensaci贸n basada en acciones alinea los intereses del director con los de los accionistas mediante el potencial de propiedad accionaria a largo plazo. La presentaci贸n se realiz贸 dentro del plazo requerido por la SEC, demostrando cumplimiento con las obligaciones de reporte de la Secci贸n 16(a).

靹滌嫕 4 鞝滌稖 靹鸽秬靷暛: Soligenix(SNGX)鞚� 鞚挫偓鞚� Jerome B. Zeldis電� 2025雲� 6鞗� 20鞚检棎 欤检嫕毵れ垬靹犿儩甓� 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 雮措秬鞛愲姅 欤茧嫻 1.70雼煬鞚� 頄夓偓 臧�瓴╈溂搿� 17,647 欤检嫕毵れ垬靹犿儩甓�鞚� 攵�鞐皼鞎橃姷雼堧嫟.

鞚� 鞓奠厴鞚� 10雲� 毵岅赴搿� 2035雲� 6鞗� 20鞚检棎 毵岆霅橂┌, 雼れ潓 雱� 彀鞐� 瓯胳硱 霃欖澕頃� 牍勳湪搿� 甓岆Μ臧� 攵�鞐惄雼堧嫟:

  • 2025雲� 9鞗� 20鞚�
  • 2025雲� 12鞗� 20鞚�
  • 2026雲� 3鞗� 20鞚�
  • 2026雲� 6鞗� 20鞚�

鞚� 欤检嫕 旮半皹 氤挫儊 攵�鞐姅 鞚挫偓鞚� 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偆氅� 鞛リ赴鞝侅澑 欤检嫕 靻岇湢 臧�電レ劚鞚� 鞝滉车頃╇媹雼�. 鞝滌稖鞚� SEC 鞖旉惮 旮瓣皠 雮挫棎 鞚措（鞏挫牳 靹轨厴 16(a) 氤搓碃 鞚橂毳� 欷�靾橅暔鞚� 氤挫棳欷嶋媹雼�.

D茅tails du d茅p么t du formulaire 4 : Jerome B. Zeldis, directeur de Soligenix (SNGX), a d茅clar茅 l'acquisition d'options d'achat d'actions le 20 juin 2025. L'initi茅 a re莽u 17 647 options d'achat d'actions avec un prix d'exercice de 1,70 $ par action.

Les options ont une dur茅e de 10 ans, expirant le 20 juin 2035, et seront acquises en quatre versements 茅gaux aux dates suivantes :

  • 20 septembre 2025
  • 20 d茅cembre 2025
  • 20 mars 2026
  • 20 juin 2026

Cette attribution de r茅mun茅ration en actions aligne les int茅r锚ts du directeur avec ceux des actionnaires via un potentiel de d茅tention d'actions 脿 long terme. Le d茅p么t a 茅t茅 effectu茅 dans les d茅lais requis par la SEC, d茅montrant la conformit茅 aux obligations de d茅claration de la Section 16(a).

Details zur Form 4 Einreichung: Jerome B. Zeldis, Direktor von Soligenix (SNGX), meldete am 20. Juni 2025 den Erwerb von Aktienoptionen. Dem Insider wurden 17.647 Aktienoptionen mit einem Aus眉bungspreis von 1,70 $ pro Aktie gew盲hrt.

Die Optionen haben eine Laufzeit von 10 Jahren und laufen am 20. Juni 2035 ab. Sie werden in vier gleichen Raten zu folgenden Terminen unverfallbar:

  • 20. September 2025
  • 20. Dezember 2025
  • 20. M盲rz 2026
  • 20. Juni 2026

Diese aktienbasierte Verg眉tung richtet die Interessen des Direktors mit denen der Aktion盲re durch langfristiges Aktienbesitzpotenzial aus. Die Meldung erfolgte fristgerecht gem盲脽 den Anforderungen der SEC und entspricht den Berichtspflichten gem盲脽 Abschnitt 16(a).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ZELDIS JEROME B
(Last) (First) (Middle)
C/O SOLIGENIX, INC.
29 EMMONS DRIVE, SUITE B-10
(Street)
PRINCETON NJ 08540
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [ SNGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.7 06/20/2025 A 17,647 (1) 06/20/2035 Common Stock 17,647 $0 17,647 D
Explanation of Responses:
1. The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026.
/s/ Jerome B. Zeldis 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did SNGX director Jerome Zeldis receive on June 20, 2025?

Jerome Zeldis received 17,647 stock options with an exercise price of $1.70 per share. These options were granted on June 20, 2025, and will expire on June 20, 2035.

What is the vesting schedule for SNGX director Zeldis's June 2025 stock options?

The stock options vest in four equal installments on: September 20, 2025, December 20, 2025, March 20, 2026, and June 20, 2026.

What position does Jerome Zeldis hold at Soligenix (SNGX)?

According to the Form 4 filing, Jerome B. Zeldis serves as a Director of Soligenix (SNGX). This is indicated by the 'X' marked in the Director box under the relationship to issuer section.

How long are Jerome Zeldis's SNGX stock options valid?

The stock options granted to Jerome Zeldis have a 10-year term, with an expiration date of June 20, 2035, as indicated in the derivative securities table of the Form 4.

What was the exercise price of SNGX stock options granted in June 2025?

The stock options were granted with an exercise price of $1.70 per share, as shown in the conversion or exercise price column of the derivative securities table.
Stock SNGX logo
Soligenix Inc

NASDAQ:SNGX

SNGX Rankings

#10182 Ranked by Market Cap
N/A Ranked by Dividends

SNGX Latest News

Jul 31, 2025
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Beh莽et's Disease
Jul 8, 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Jul 1, 2025
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Jun 6, 2025
Soligenix Highlights Dr. Ellen Kim鈥檚 Recent Q&A and the Promise of HyBryte鈩� in Ongoing Clinical Trials
May 9, 2025
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

SNGX Latest SEC Filings

Jul 31, 2025
[8-K] Soligenix, Inc. Reports Material Event
Jun 20, 2025
[Form 4] Soligenix, Inc. Insider Trading Activity
Jun 20, 2025
[Form 4] Soligenix, Inc. Insider Trading Activity
Jun 20, 2025
[Form 4] Soligenix, Inc. Insider Trading Activity
Jun 20, 2025
[S-8] Soligenix, Inc. Employee Benefit Plan Registration

SNGX Stock Data

4.08M
3.26M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
United States
PRINCETON